Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective.

Olivieri, Anamaria-Vera; Muratov, Sergey; Larsen, Sara; Luckevich, Maria; Chan, Katalina; Lamotte, Mark; Lau, David C W

Olivieri, Anamaria-Vera; Muratov, Sergey; Larsen, Sara; Luckevich, Maria; Chan, Katalina; Lamotte, Mark; Lau, David C W.

Affiliation

Olivieri AV; QVIA, Basel, Switzerland.
Muratov S; QVIA Mississauga, Mississauga, ON, Canada.
Larsen S; Novo Nordisk A/S, Søborg, Bagsværd, Denmark.
Luckevich M; Novo Nordisk Canada Inc, Mississauga, ON, Canada. MLVH@novonordisk.com.
Chan K; Novo Nordisk Canada Inc, Mississauga, ON, Canada.
Lamotte M; QVIA, Zaventem, Zaventem, Belgium.
Lau DCW; Department of Medicine, University of Calgary Cumming School of Medicine, Calgary, AB, Canada.

Int J Obes (Lond) ; 48(5): 683-693, 2024 May.

Article in En | MEDLINE | ID: mdl-38291203

Subject(s)

Anti-Obesity Agents; Cost-Benefit Analysis; Obesity; Orlistat; Humans; Canada; Middle Aged; Obesity/drug therapy; Obesity/economics; Female; Anti-Obesity Agents/therapeutic use; Anti-Obesity Agents/economics; Male; Orlistat/therapeutic use; Quality-Adjusted Life Years; Liraglutide/therapeutic use; Liraglutide/economics; Diabetes Mellitus, Type 2/drug therapy; Diabetes Mellitus, Type 2/economics; Bupropion/therapeutic use; Bupropion/economics; Naltrexone/therapeutic use; Naltrexone/economics; Glucagon-Like Peptides/therapeutic use; Glucagon-Like Peptides/economics

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Cost-Benefit Analysis / Anti-Obesity Agents / Orlistat / Obesity Type of study: Health_economic_evaluation / Prognostic_studies Limits: Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Year: 2024 Type: Article

Fulltext

XML

PubMed Links

Search on Google